Craft

Immuron

Stock Price

$0.1

2024-10-28

Market Capitalization

$17.6 M

2024-10-28

Revenue

$7.3 M

FY, 2025

Immuron Summary

Company Summary

Overview
Immuron is a microbiome company focused on developing oral immunotherapeutics for the treatment of gut mediated diseases. The company markets Travelan, an immune supplement that can be taken to reduce the risk of diarrhea and the symptoms of minor gastrointestinal disorders. It also offers Protectyn, a dietary supplement that helps maintain healthy digestive function and support the liver.
Type
Public
Status
Active
Founded
1994
HQ
Blackburn North, AU | view all locations
Website
https://www.immuron.com.au/
Cybersecurity rating
Sectors

Key People

  • Daniel Pollock, Non-Executive Director

    • Reza Moussakhani, Manufacturing Quality Director

      • Phillip Hains, Company Secretary & Chief Financial Officer

        • Ravi Savarirayan, Non-Executive Director

          LocationsView all

          1 location detected

          • Blackburn North, VIC HQ

            Australia

            Factory 10 A/25-37 Chapman St

          Immuron Financials

          Summary Financials

          Revenue (H1, 2026)
          $4.2M
          Gross profit (H1, 2026)
          $3.0M
          Net income (H1, 2026)
          ($1.9M)
          Cash (H1, 2026)
          $10.0M
          EBIT (H1, 2026)
          ($2.0M)

          Footer menu